The FDA’s Office of Regulatory Affairs (ORA) Ombudsman assists external and internal stakeholders who are unable to resolve problems directly with ORA.  The Ombudsman will use this survey to obtain feedback to assess the needs of stakeholders which will improve the Ombudsman service. The ORA Ombudsman customer service survey does not replace existing formal complaint mechanisms and is not intended to measure satisfaction with ORA regulatory decisions. 
Your participation / nonparticipation is completely voluntary, and your responses will not have an effect on your eligibility for receipt of any FDA services. Please do not provide any personally identifiable information within any questions on this survey. All data collected will be kept private to the fullest extent allowed by law.
OMB Control No. 0910-0360, expires 10/31/2023

Question Title

* 1. How would you rate your experience with the ORA Ombudsman Program?

Question Title

* 2. When was your most recent encounter with the ORA Ombudsman Program?

Question Title

* 3. How did you hear about the ORA Ombudsman Program?

Question Title

* 4. To what degree do you agree or disagree with the following statements:

  Strongly Agree Agree Neither Agree nor Disagree Disagree Strongly Disagree
The Ombudsman listened to my concerns in an open and fair manner.
The Ombudsman was able to clearly understand the problem I was presenting.
The Ombudsman informed me about relevant policies and resources.
As a result of contacting the ORA Ombudsman Program, I have more options for resolving my complaint or dispute.
I feel confident about the privacy of my interaction with the Ombudsman.
I was able to speak with the Ombudsman in a reasonable period of time.
I was provided updates on the status of my inquiry.

Question Title

* 5. If you had not contacted the Ombudsman, would you have used a formal channel such as appeal procedures or legal action to address your concern?

Question Title

* 6. Please help us understand who you are by selecting the choice that applies to you:

Question Title

* 7. Have you visited the ORA Ombudsman website, www.fda.gov/ORAOmbudsman?

T